TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Neoantigen Cancer Vaccine Market Insights and Forecast to 2028

Global Neoantigen Cancer Vaccine Market Insights and Forecast to 2028

  • Category:Life Sciences
  • Published on : 02 September 2022
  • Pages :111
  • Formats:
  • Report Code:SMR-7318900
OfferClick for best price

Best Price: $3920

Neoantigen Cancer Vaccine Market Size, Share 2022


Market Analysis and Insights: Global Neoantigen Cancer Vaccine Market

The global Neoantigen Cancer Vaccine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neoantigen Cancer Vaccine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neoantigen Cancer Vaccine market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neoantigen Cancer Vaccine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neoantigen Cancer Vaccine market.

Global Neoantigen Cancer Vaccine Scope and Market Size

Neoantigen Cancer Vaccine market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Neoantigen Cancer Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

Personalized Vaccine

Off-the-shelf Neovaccines

Segment by Application

Hospital

Clinic

Others

By Company

Roche

Medimmune

Merck

Advaxis

Agenus

Genocea

Gritstone Oncology

Neon Therapeutics

Nouscom

OSE Immunotherapeutics

Medigene

Vaccibody

Brightpath Biotherapeutics

Geneos Therapeutics

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Neoantigen Cancer Vaccine product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Neoantigen Cancer Vaccine, with price, sales, revenue, and global market share of Neoantigen Cancer Vaccine from 2019 to 2022.

Chapter 3, the Neoantigen Cancer Vaccine competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Neoantigen Cancer Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Neoantigen Cancer Vaccine market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Neoantigen Cancer Vaccine.

Chapter 13, 14, and 15, to describe Neoantigen Cancer Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Neoantigen Cancer Vaccine Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Neoantigen Cancer Vaccine Market Insights and Forecast to 2028
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 111 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Personalized Vaccine
1.2.3 Off-the-shelf Neovaccines
1.3 Market by Application
1.3.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neoantigen Cancer Vaccine Market Perspective (2017-2028)
2.2 Neoantigen Cancer Vaccine Growth Trends by Region
2.2.1 Neoantigen Cancer Vaccine Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neoantigen Cancer Vaccine Historic Market Size by Region (2017-2022)
2.2.3 Neoantigen Cancer Vaccine Forecasted Market Size by Region (2023-2028)
2.3 Neoantigen Cancer Vaccine Market Dynamics
2.3.1 Neoantigen Cancer Vaccine Industry Trends
2.3.2 Neoantigen Cancer Vaccine Market Drivers
2.3.3 Neoantigen Cancer Vaccine Market Challenges
2.3.4 Neoantigen Cancer Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neoantigen Cancer Vaccine Players by Revenue
3.1.1 Global Top Neoantigen Cancer Vaccine Players by Revenue (2017-2022)
3.1.2 Global Neoantigen Cancer Vaccine Revenue Market Share by Players (2017-2022)
3.2 Global Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neoantigen Cancer Vaccine Revenue
3.4 Global Neoantigen Cancer Vaccine Market Concentration Ratio
3.4.1 Global Neoantigen Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Cancer Vaccine Revenue in 2021
3.5 Neoantigen Cancer Vaccine Key Players Head office and Area Served
3.6 Key Players Neoantigen Cancer Vaccine Product Solution and Service
3.7 Date of Enter into Neoantigen Cancer Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neoantigen Cancer Vaccine Breakdown Data by Type
4.1 Global Neoantigen Cancer Vaccine Historic Market Size by Type (2017-2022)
4.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2023-2028)
5 Neoantigen Cancer Vaccine Breakdown Data by Application
5.1 Global Neoantigen Cancer Vaccine Historic Market Size by Application (2017-2022)
5.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neoantigen Cancer Vaccine Market Size (2017-2028)
6.2 North America Neoantigen Cancer Vaccine Market Size by Type
6.2.1 North America Neoantigen Cancer Vaccine Market Size by Type (2017-2022)
6.2.2 North America Neoantigen Cancer Vaccine Market Size by Type (2023-2028)
6.2.3 North America Neoantigen Cancer Vaccine Market Share by Type (2017-2028)
6.3 North America Neoantigen Cancer Vaccine Market Size by Application
6.3.1 North America Neoantigen Cancer Vaccine Market Size by Application (2017-2022)
6.3.2 North America Neoantigen Cancer Vaccine Market Size by Application (2023-2028)
6.3.3 North America Neoantigen Cancer Vaccine Market Share by Application (2017-2028)
6.4 North America Neoantigen Cancer Vaccine Market Size by Country
6.4.1 North America Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
6.4.2 North America Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Neoantigen Cancer Vaccine Market Size (2017-2028)
7.2 Europe Neoantigen Cancer Vaccine Market Size by Type
7.2.1 Europe Neoantigen Cancer Vaccine Market Size by Type (2017-2022)
7.2.2 Europe Neoantigen Cancer Vaccine Market Size by Type (2023-2028)
7.2.3 Europe Neoantigen Cancer Vaccine Market Share by Type (2017-2028)
7.3 Europe Neoantigen Cancer Vaccine Market Size by Application
7.3.1 Europe Neoantigen Cancer Vaccine Market Size by Application (2017-2022)
7.3.2 Europe Neoantigen Cancer Vaccine Market Size by Application (2023-2028)
7.3.3 Europe Neoantigen Cancer Vaccine Market Share by Application (2017-2028)
7.4 Europe Neoantigen Cancer Vaccine Market Size by Country
7.4.1 Europe Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
7.4.2 Europe Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size (2017-2028)
8.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type
8.2.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Neoantigen Cancer Vaccine Market Share by Type (2017-2028)
8.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application
8.3.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Neoantigen Cancer Vaccine Market Share by Application (2017-2028)
8.4 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region
8.4.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neoantigen Cancer Vaccine Market Size (2017-2028)
9.2 Latin America Neoantigen Cancer Vaccine Market Size by Type
9.2.1 Latin America Neoantigen Cancer Vaccine Market Size by Type (2017-2022)
9.2.2 Latin America Neoantigen Cancer Vaccine Market Size by Type (2023-2028)
9.2.3 Latin America Neoantigen Cancer Vaccine Market Share by Type (2017-2028)
9.3 Latin America Neoantigen Cancer Vaccine Market Size by Application
9.3.1 Latin America Neoantigen Cancer Vaccine Market Size by Application (2017-2022)
9.3.2 Latin America Neoantigen Cancer Vaccine Market Size by Application (2023-2028)
9.3.3 Latin America Neoantigen Cancer Vaccine Market Share by Application (2017-2028)
9.4 Latin America Neoantigen Cancer Vaccine Market Size by Country
9.4.1 Latin America Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
9.4.2 Latin America Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size (2017-2028)
10.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type
10.2.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Neoantigen Cancer Vaccine Market Share by Type (2017-2028)
10.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application
10.3.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Neoantigen Cancer Vaccine Market Share by Application (2017-2028)
10.4 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country
10.4.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Neoantigen Cancer Vaccine Introduction
11.1.4 Roche Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.1.5 Roche Recent Developments
11.2 Medimmune
11.2.1 Medimmune Company Details
11.2.2 Medimmune Business Overview
11.2.3 Medimmune Neoantigen Cancer Vaccine Introduction
11.2.4 Medimmune Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.2.5 Medimmune Recent Developments
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Neoantigen Cancer Vaccine Introduction
11.3.4 Merck Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.3.5 Merck Recent Developments
11.4 Advaxis
11.4.1 Advaxis Company Details
11.4.2 Advaxis Business Overview
11.4.3 Advaxis Neoantigen Cancer Vaccine Introduction
11.4.4 Advaxis Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.4.5 Advaxis Recent Developments
11.5 Agenus
11.5.1 Agenus Company Details
11.5.2 Agenus Business Overview
11.5.3 Agenus Neoantigen Cancer Vaccine Introduction
11.5.4 Agenus Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.5.5 Agenus Recent Developments
11.6 Genocea
11.6.1 Genocea Company Details
11.6.2 Genocea Business Overview
11.6.3 Genocea Neoantigen Cancer Vaccine Introduction
11.6.4 Genocea Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.6.5 Genocea Recent Developments
11.7 Gritstone Oncology
11.7.1 Gritstone Oncology Company Details
11.7.2 Gritstone Oncology Business Overview
11.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Introduction
11.7.4 Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.7.5 Gritstone Oncology Recent Developments
11.8 Neon Therapeutics
11.8.1 Neon Therapeutics Company Details
11.8.2 Neon Therapeutics Business Overview
11.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Introduction
11.8.4 Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.8.5 Neon Therapeutics Recent Developments
11.9 Nouscom
11.9.1 Nouscom Company Details
11.9.2 Nouscom Business Overview
11.9.3 Nouscom Neoantigen Cancer Vaccine Introduction
11.9.4 Nouscom Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.9.5 Nouscom Recent Developments
11.10 OSE Immunotherapeutics
11.10.1 OSE Immunotherapeutics Company Details
11.10.2 OSE Immunotherapeutics Business Overview
11.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Introduction
11.10.4 OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.10.5 OSE Immunotherapeutics Recent Developments
11.11 Medigene
11.11.1 Medigene Company Details
11.11.2 Medigene Business Overview
11.11.3 Medigene Neoantigen Cancer Vaccine Introduction
11.11.4 Medigene Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.11.5 Medigene Recent Developments
11.12 Vaccibody
11.12.1 Vaccibody Company Details
11.12.2 Vaccibody Business Overview
11.12.3 Vaccibody Neoantigen Cancer Vaccine Introduction
11.12.4 Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.12.5 Vaccibody Recent Developments
11.13 Brightpath Biotherapeutics
11.13.1 Brightpath Biotherapeutics Company Details
11.13.2 Brightpath Biotherapeutics Business Overview
11.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Introduction
11.13.4 Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.13.5 Brightpath Biotherapeutics Recent Developments
11.14 Geneos Therapeutics
11.14.1 Geneos Therapeutics Company Details
11.14.2 Geneos Therapeutics Business Overview
11.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Introduction
11.14.4 Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022)
11.14.5 Geneos Therapeutics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Personalized Vaccine
Table 3. Key Players of Off-the-shelf Neovaccines
Table 4. Global Neoantigen Cancer Vaccine Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Neoantigen Cancer Vaccine Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Neoantigen Cancer Vaccine Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Neoantigen Cancer Vaccine Market Share by Region (2017-2022)
Table 8. Global Neoantigen Cancer Vaccine Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Neoantigen Cancer Vaccine Market Share by Region (2023-2028)
Table 10. Neoantigen Cancer Vaccine Market Trends
Table 11. Neoantigen Cancer Vaccine Market Drivers
Table 12. Neoantigen Cancer Vaccine Market Challenges
Table 13. Neoantigen Cancer Vaccine Market Restraints
Table 14. Global Neoantigen Cancer Vaccine Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Neoantigen Cancer Vaccine Revenue Share by Players (2017-2022)
Table 16. Global Top Neoantigen Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Cancer Vaccine as of 2021)
Table 17. Ranking of Global Top Neoantigen Cancer Vaccine Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Neoantigen Cancer Vaccine Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Neoantigen Cancer Vaccine Product Solution and Service
Table 21. Date of Enter into Neoantigen Cancer Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Neoantigen Cancer Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2017-2022)
Table 25. Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2023-2028)
Table 27. Global Neoantigen Cancer Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Neoantigen Cancer Vaccine Revenue Share by Application (2017-2022)
Table 29. Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Neoantigen Cancer Vaccine Revenue Share by Application (2023-2028)
Table 31. North America Neoantigen Cancer Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 32. North America Neoantigen Cancer Vaccine Market Size by Type (2023-2028) & (US$ Million)
Table 33. North America Neoantigen Cancer Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 34. North America Neoantigen Cancer Vaccine Market Size by Application (2023-2028) & (US$ Million)
Table 35. North America Neoantigen Cancer Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Neoantigen Cancer Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Neoantigen Cancer Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 38. Europe Neoantigen Cancer Vaccine Market Size by Type (2023-2028) & (US$ Million)
Table 39. Europe Neoantigen Cancer Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 40. Europe Neoantigen Cancer Vaccine Market Size by Application (2023-2028) & (US$ Million)
Table 41. Europe Neoantigen Cancer Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 42. Europe Neoantigen Cancer Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific Neoantigen Cancer Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific Neoantigen Cancer Vaccine Market Size by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific Neoantigen Cancer Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Neoantigen Cancer Vaccine Market Size by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Neoantigen Cancer Vaccine Market Size by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Neoantigen Cancer Vaccine Market Size by Region (2023-2028) & (US$ Million)
Table 49. Latin America Neoantigen Cancer Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 50. Latin America Neoantigen Cancer Vaccine Market Size by Type (2023-2028) & (US$ Million)
Table 51. Latin America Neoantigen Cancer Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 52. Latin America Neoantigen Cancer Vaccine Market Size by Application (2023-2028) & (US$ Million)
Table 53. Latin America Neoantigen Cancer Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 54. Latin America Neoantigen Cancer Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Neoantigen Cancer Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 56. Middle East and Africa Neoantigen Cancer Vaccine Market Size by Type (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Neoantigen Cancer Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Neoantigen Cancer Vaccine Market Size by Application (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Neoantigen Cancer Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Neoantigen Cancer Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 61. Roche Company Details
Table 62. Roche Business Overview
Table 63. Roche Neoantigen Cancer Vaccine Product
Table 64. Roche Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 65. Roche Recent Developments
Table 66. Medimmune Company Details
Table 67. Medimmune Business Overview
Table 68. Medimmune Neoantigen Cancer Vaccine Product
Table 69. Medimmune Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 70. Medimmune Recent Developments
Table 71. Merck Company Details
Table 72. Merck Business Overview
Table 73. Merck Neoantigen Cancer Vaccine Product
Table 74. Merck Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 75. Merck Recent Developments
Table 76. Advaxis Company Details
Table 77. Advaxis Business Overview
Table 78. Advaxis Neoantigen Cancer Vaccine Product
Table 79. Advaxis Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 80. Advaxis Recent Developments
Table 81. Agenus Company Details
Table 82. Agenus Business Overview
Table 83. Agenus Neoantigen Cancer Vaccine Product
Table 84. Agenus Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 85. Agenus Recent Developments
Table 86. Genocea Company Details
Table 87. Genocea Business Overview
Table 88. Genocea Neoantigen Cancer Vaccine Product
Table 89. Genocea Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 90. Genocea Recent Developments
Table 91. Gritstone Oncology Company Details
Table 92. Gritstone Oncology Business Overview
Table 93. Gritstone Oncology Neoantigen Cancer Vaccine Product
Table 94. Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 95. Gritstone Oncology Recent Developments
Table 96. Neon Therapeutics Company Details
Table 97. Neon Therapeutics Business Overview
Table 98. Neon Therapeutics Neoantigen Cancer Vaccine Product
Table 99. Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 100. Neon Therapeutics Recent Developments
Table 101. Nouscom Company Details
Table 102. Nouscom Business Overview
Table 103. Nouscom Neoantigen Cancer Vaccine Product
Table 104. Nouscom Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 105. Nouscom Recent Developments
Table 106. OSE Immunotherapeutics Company Details
Table 107. OSE Immunotherapeutics Business Overview
Table 108. OSE Immunotherapeutics Neoantigen Cancer Vaccine Product
Table 109. OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 110. OSE Immunotherapeutics Recent Developments
Table 111. Medigene Company Details
Table 112. Medigene Business Overview
Table 113. Medigene Neoantigen Cancer Vaccine Product
Table 114. Medigene Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 115. Medigene Recent Developments
Table 116. Vaccibody Company Details
Table 117. Vaccibody Business Overview
Table 118. Vaccibody Neoantigen Cancer Vaccine Product
Table 119. Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 120. Vaccibody Recent Developments
Table 121. Brightpath Biotherapeutics Company Details
Table 122. Brightpath Biotherapeutics Business Overview
Table 123. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product
Table 124. Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 125. Brightpath Biotherapeutics Recent Developments
Table 126. Geneos Therapeutics Company Details
Table 127. Geneos Therapeutics Business Overview
Table 128. Geneos Therapeutics Neoantigen Cancer Vaccine Product
Table 129. Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2017-2022) & (US$ Million)
Table 130. Geneos Therapeutics Recent Developments
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neoantigen Cancer Vaccine Market Share by Type: 2021 VS 2028
Figure 2. Personalized Vaccine Features
Figure 3. Off-the-shelf Neovaccines Features
Figure 4. Global Neoantigen Cancer Vaccine Market Share by Application: 2021 VS 2028
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Others Case Studies
Figure 8. Neoantigen Cancer Vaccine Report Years Considered
Figure 9. Global Neoantigen Cancer Vaccine Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Neoantigen Cancer Vaccine Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Neoantigen Cancer Vaccine Market Share by Region: 2021 VS 2028
Figure 12. Global Neoantigen Cancer Vaccine Market Share by Players in 2021
Figure 13. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Cancer Vaccine as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Neoantigen Cancer Vaccine Revenue in 2021
Figure 15. North America Neoantigen Cancer Vaccine Market Size YoY (2017-2028) & (US$ Million)
Figure 16. North America Neoantigen Cancer Vaccine Market Size Market Share by Type (2017-2028)
Figure 17. North America Neoantigen Cancer Vaccine Market Size Market Share by Application (2017-2028)
Figure 18. North America Neoantigen Cancer Vaccine Market Size Share by Country (2017-2028)
Figure 19. United States Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Neoantigen Cancer Vaccine Market Size YoY (2017-2028) & (US$ Million)
Figure 22. Europe Neoantigen Cancer Vaccine Market Size Market Share by Type (2017-2028)
Figure 23. Europe Neoantigen Cancer Vaccine Market Size Market Share by Application (2017-2028)
Figure 24. Europe Neoantigen Cancer Vaccine Market Size Share by Country (2017-2028)
Figure 25. Germany Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Neoantigen Cancer Vaccine Market Size YoY (2017-2028) & (US$ Million)
Figure 32. Asia Pacific Neoantigen Cancer Vaccine Market Size Market Share by Type (2017-2028)
Figure 33. Asia Pacific Neoantigen Cancer Vaccine Market Size Market Share by Application (2017-2028)
Figure 34. Asia Pacific Neoantigen Cancer Vaccine Market Size Share by Region (2017-2028)
Figure 35. China Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 41. Latin America Neoantigen Cancer Vaccine Market Size YoY (2017-2028) & (US$ Million)
Figure 42. Latin America Neoantigen Cancer Vaccine Market Size Market Share by Type (2017-2028)
Figure 43. Latin America Neoantigen Cancer Vaccine Market Size Market Share by Application (2017-2028)
Figure 44. Latin America Neoantigen Cancer Vaccine Market Size Share by Country (2017-2028)
Figure 45. Mexico Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Brazil Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Middle East & Africa Neoantigen Cancer Vaccine Market Size YoY (2017-2028) & (US$ Million)
Figure 48. Middle East and Africa Neoantigen Cancer Vaccine Market Size Market Share by Type (2017-2028)
Figure 49. Middle East and Africa Neoantigen Cancer Vaccine Market Size Market Share by Application (2017-2028)
Figure 50. Middle East and Africa Neoantigen Cancer Vaccine Market Size Share by Country (2017-2028)
Figure 51. Turkey Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Saudi Arabia Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. UAE Neoantigen Cancer Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Roche Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 55. Medimmune Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 56. Merck Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 57. Advaxis Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 58. Agenus Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 59. Genocea Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 60. Gritstone Oncology Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 61. Neon Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 62. Nouscom Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 63. OSE Immunotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 64. Medigene Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 65. Vaccibody Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 66. Brightpath Biotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 67. Geneos Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2017-2022)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount